PO.BCS02.06 · 生物信息与计算
基于人工智能对可穿戴设备衍生生物特征的分析以刻画实体器官癌症化疗的生理反应
Artificial intelligence-derived analysis of wearables-derived biometrics to characterize physiologic response to chemotherapy in solid organ cancers
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
目的:(1)利用可穿戴设备衍生的生物特征来考察实体器官癌症化疗期间生理模式与不良事件之间的关系。(2)利用对这些生理模式的机器学习分析来预测不良事件。
方法:接受全身治疗的实体器官癌症患者被纳入一项正在进行的评估化疗/免疫治疗对生理模式影响的试验。患者在治疗前及治疗期间连续佩戴Fitbit超过5天。我们分析了跨疗程的标准化每日平均静息心率(RHR)的个体内和个体间变异。我们基于Change-of-Heart机器学习算法开发了一个新颖的、个体化的、以基线为参照的统计框架,称为“HeartSense”,它将每位参与者的RHR相对于其自身在睡眠和非睡眠期间的基线进行标准化,生成一个量化每日生理稳定性的评分。评分越高反映RHR模式与治疗前基线越一致,评分越低则表示偏离基线越大。我们比较了第1疗程中发生不良事件患者与未发生不良事件患者的最低HeartSense评分。我们还考察了第1疗程的评分是否与第2疗程的不良事件相关。
结果:共有54例接受了超过1个疗程全身治疗的癌症患者被纳入分析。治疗期间出现了独特的生理模式。一例患者在每次输注后表现出心率的周期性下降并恢复至基线(图A),而另一例患者则表现出在治疗终止前进行性的生理紊乱(图B)。睡眠和非睡眠RHR的个体内变异显著小于个体间变异(图C)。一个疗程内HeartSense中位评分较低者显著更可能经历不良事件(图D)。较低的评分也与第2疗程的不良事件相关(图E)。
结论:患者在全身治疗期间静息心率表现出独特的生理变化,偏离正常模式可能提示与治疗相关的不良事件。我们新颖的机器学习算法发现,较低的评分——反映生理调节异常——与当前治疗疗程期间及之后不良事件的较高风险相关,提示化疗相关毒性可能有早期生理预警信号先行出现。
查看英文原文 English abstract
Objective: (1) To use wearable-derived biometrics to examine the relationship between physiologic patterns and adverse events during chemotherapy for solid organ cancers. (2) To use machine-learning analysis of these physiologic patterns to predict adverse events.
Methods: Patients with solid organ cancers receiving systemic therapy were enrolled in an ongoing trial evaluating the effects of chemotherapy/ immunotherapy on physiologic patterns. Patients continuously wore a Fitbit for >5 days before and during treatment. We analyzed intra- and inter-personal variation in normalized daily average resting heart rate (RHR) across cycles. We developed a novel, personalized, baseline-referenced statistical framework based on the Change-of-Heart machine learning algorithm, “HeartSense,” which standardizes each participant's RHR against their own baseline during sleep and non-sleep periods, generating a score that quantifies daily physiologic stability. Higher scores reflect RHR patterns consistent with pre-treatment baseline and lower scores indicate greater deviation from baseline. We compared lowest HeartSense scores by patients who experienced adverse events vs those who did not in cycle 1. We also examined whether scores from cycle 1 were associated with adverse events in cycle 2.
Results: A total of 54 cancer patients who underwent > 1 cycle of systemic therapy were included in analysis. Distinct physiologic patterns emerged during therapy. One patient showed cyclic decreases in heart rate after each infusion with recovery to baseline (Figure A), while another exhibited progressive physiologic disruption preceding treatment termination (Figure B). Intrapersonal variation in sleep and non-sleep RHR was significantly smaller than interpersonal variation (Figure C). Lower median HeartSense scores within a cycle were significantly more likely to experience adverse events (Figure D). Lower scores were also associated with adverse events in cycle 2 (Figure E).
Conclusions: Patients exhibit distinct physiologic changes in resting heart rate during systemic therapy and deviation from normal patterns may indicate treatment-related adverse events. Our novel machine learning algorithm identified that lower scores-reflecting abnormal physiologic regulation-were linked to a higher risk of adverse events both during and after the current treatment cycle, suggesting that chemotherapy-related toxicity can be preceded by early physiologic warning signals.
利益披露 Disclosure
A. Zhu, None..
L. Zhang, None..
Y. Zhang, None..
A. Potter, None..
B. Rettner, None..
A. Keshwani, None..
A. Keshwani, None..
N. Hu, None..
A. Melki, None..
Z. Fang, None..
M. McCarthy, None..
J. Baird, None..
A. Pope, None..
S. Schwartz, None..
Q. Guo, None..
M. Lanuti, None..
X. Li, None.
C. Yang,
AstraZeneca ), Other, Advisory Board
Honoraria from AstraZeneca
Grant from AstraZeneca.
Genentech Other, Advisory Board.